Its expression increases progressively with the malignancy of MM, and CCT3 may promote tumor progression by regulating Myelocytomatosis oncogene through the JAK–STAT3 signaling pathway.[23] Liu D et al[85] demonstrated that circ-CCT3 is upregulated in bortezomib-resistant MM cells. The gene discussed is STAT3; the disease is Miyoshi myopathy.